Download PDF
Semin Vasc Med 2001; 01(1): 043-054
DOI: 10.1055/s-2001-14669
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Treatment of Deep Vein Thrombosis

Francis Couturaud, Clive Kearon
  • McMaster Clinic, Henderson General Hospital, Hamilton, Ontario, Canada
Further Information

Publication History

Publication Date:
31 December 2001 (online)

    Permissions and Reprints

ABSTRACT

Most patients who present with deep vein thrombosis (DVT) can be treated with weight-adjusted, fixed-dose, low molecular heparin as an outpatient. The subsequent duration of oral anticoagulant therapy should be individualized according to the risk of recurrent venous thromboembolism and the risk of anticoagulant-induced bleeding. The risk of recurrence is low if thrombosis was provoked by a major reversible risk factor such as surgery; 3 months of treatment is usually adequate for such patients. The risk of recurrence is high if thrombosis was unprovoked (``idiopathic'') or associated with a nonreversible risk factor such as active cancer; at least 6 months, and sometimes indefinite, anticoagulant therapy is indicated for such patients. The presence of an antiphospholipid antibody, and other selected thrombophilic states, favors more prolonged therapy within each of the categories noted previously. Systemic thrombolytic therapy helps to restore venous patency and probably reduces the risk of the postthrombotic syndrome; however, it is associated with an unacceptable risk of bleeding. Catheter-directed thromboylsis, particularly for isolated iliofemoral thrombosis, may be beneficial and needs further evaluation in controlled trials.

KEYWORD

Deep vein thrombosis - treatment - anticoagulant therapy - thrombolytic therapy - heparin - warfarin

REFERENCES

  • 1 Prandoni P, Lensing A WA, Cogo A. The long-term clinical course of acute deep venous thrombosis.  Ann Intern Med . 1996;  125 1-7
    CrossrefPubMedGoogle Scholar
  • 2 Hull R, Delmore T, Genton E. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.  N Engl J Med . 1979;  301 855-858
    CrossrefPubMedGoogle Scholar
  • 3 Coon W W, Willis P W. Recurrence of venous thromboembolism.  Surgery . 1973;  73 823-827
    PubMedGoogle Scholar
  • 4 Douketis J D, Kearon C, Bates S, Duku E K, Ginsberg J S. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism.  JAMA . 1998;  279 458-462
    CrossrefPubMedGoogle Scholar
  • 5 Brandjes D PM, Heijboer H, Buller H R, de Rijk M, Jagt H, ten Cate W J. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.  N Engl J Med . 1992;  327 1485-1489
    CrossrefPubMedGoogle Scholar
  • 6 Hull R D, Raskob G E, Brant R F, Pineo G F, Valentine K A. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.  Arch Intern Med . 1997;  157 2562-2568
    CrossrefPubMedGoogle Scholar
  • 7 Hull R D, Raskob G, Brant R F, Pineo G F, Valentine K A. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy.  Arch Intern Med . 1997;  157 2317-2321
    CrossrefPubMedGoogle Scholar
  • 8 Ginsberg J. Management of venous thromboembolism.  N Engl J Med . 1996;  335 1816-1828
    CrossrefPubMedGoogle Scholar
  • 9 Hirsh J, Warkentin T E, Raschke R, Granger C B, Ohman M, Dalen J E. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.  Chest . 1998;  114 489S-510S
    PubMedGoogle Scholar
  • 10 Raschke R A, Reilly B M, Guidry J R, Fontana J R, Srinivas S. The weight-based heparin dosing nomogram compared with a ``standard care'' nomogram.  Ann Intern Med . 1993;  119 874-881
    CrossrefPubMedGoogle Scholar
  • 11 Prandoni P, Bagatella P, Bernardi E. Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis.  Ann Intern Med . 1998;  129 299-302
    PubMedGoogle Scholar
  • 12 Kearon C, Harrison L, Crowther M, Ginsberg J S. Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis.  Thromb Res . 2000;  97 395-403
    CrossrefPubMedGoogle Scholar
  • 13 Anand S, Ginsberg J S, Kearon C, Gent M, Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.  Arch Intern Med . 1996;  156 1677-1681
    CrossrefPubMedGoogle Scholar
  • 14 Anand S S, Bates S, Ginsberg J S. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin time results.  Arch Intern Med . 1999;  159 2029-2032
    CrossrefPubMedGoogle Scholar
  • 15 Bernardi E, Piccioli A, Oliboni G, Zuin R, Girolami A, Prandoni P. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism-an overview.  Thromb Haemost . 2000;  84 22-26
    PubMedGoogle Scholar
  • 16 Gallus A S, Jackaman J, Tillett J, Mills W, Sycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.  Lancet . 1986;  2 1293-1296
    PubMedGoogle Scholar
  • 17 Hull R D, Raskob G E, Rosenbloom D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.  N Engl J Med . 1990;  322 1260-1264
    PubMedGoogle Scholar
  • 18 Leizorovicz A, Simonneau G, Decousus H, Boissel J P. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: meta-analysis.  Br Med J . 1994;  309 299-304
    PubMedGoogle Scholar
  • 19 Lensing A WA, Prins M H, Davidson B L, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins.  Arch Intern Med . 1995;  155 601-607
    CrossrefPubMedGoogle Scholar
  • 20 Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg J S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.  Am J Med . 1996;  100 269-277
    CrossrefPubMedGoogle Scholar
  • 21 Levine M, Gent M, Hirsh J. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.  N Engl J Med . 1996;  334 677-681
    CrossrefPubMedGoogle Scholar
  • 22 Koopman M MW, Prandoni P, Piovella F. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home.  N Engl J Med . 1996;  334 682-687
    CrossrefPubMedGoogle Scholar
  • 23 Luomanmäki K, Grankvist S, Hallert C. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.  J Intern Med . 1996;  240 85-92
    CrossrefPubMedGoogle Scholar
  • 24 The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism.  N Engl J Med . 1997;  337 657-662
    CrossrefPubMedGoogle Scholar
  • 25 Simonneau G, Sors H, Charbonnier B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism.  N Engl J Med . 1997;  337 663-669
    CrossrefPubMedGoogle Scholar
  • 26 Decousus H, Leizorovicz A, Parent F. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis.  N Engl J Med . 1998;  338 409-415
    CrossrefPubMedGoogle Scholar
  • 27 Harenberg J, Schmidt J A, Koppenhagen K, Tolle A, Huisman M V, Buller H R. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.  Thromb Haemost . 2000;  83 652-656
    PubMedGoogle Scholar
  • 28 Dolovich L R, Ginsberg J S, Douketis J D, Holbrook A M, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.  Arch Intern Med . 2000;  160 181-188
    CrossrefPubMedGoogle Scholar
  • 29 Gould M K, Dembitzer A D, Doyle R L, Hastie T J, Garber A M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.  Ann Intern Med . 1999;  130 800-809
    CrossrefPubMedGoogle Scholar
  • 30 Zacharski L R, Ornstein D L. Heparin and Cancer.  Thromb Haemost . 1998;  80 10-23
    PubMedGoogle Scholar
  • 31 Boccalon H, Elias A, Chale J J, Cadene A, Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study.  Arch Intern Med . 2000;  160 1769-1773
    CrossrefPubMedGoogle Scholar
  • 32 Wells P S, Kovacs M J, Bormanis J. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin.  Arch Intern Med . 1998;  158 1809-1812
    CrossrefPubMedGoogle Scholar
  • 33 Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin.  Arch Intern Med . 1998;  158 2001-2003
    CrossrefPubMedGoogle Scholar
  • 34 Van den Belt G M A, Bossuyt P MM, Prins M H, Gallus A S, Buller H R. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis-an economic evaluation.  Thromb Haemost . 1998;  79 259-263
    PubMedGoogle Scholar
  • 35 Gould M K, Dembitzer A D, Sanders G D, Garber A M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.  Ann Intern Med . 1999;  130 789-799
    PubMedGoogle Scholar
  • 36 Rodger M, Bredeson C, Wells P S, Beck J, Kearns B, Huebsch L B. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.  CMAJ . 1998;  159 931-938
    PubMedGoogle Scholar
  • 37 O'Brien B, Levine M, Willan A. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis.  Arch Intern Med . 1999;  159 2298-2304
    CrossrefPubMedGoogle Scholar
  • 38 Holmstrom M, Berglund S, Granquist S, Bratt G, Tornebohm E, Lockner D. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg.  Thromb Res . 1992;  67 49-55
    CrossrefPubMedGoogle Scholar
  • 39 Partsch H, Kechavarz B, Mostbeck A, Köhn H, Lipp C. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin.  J Vasc Surg . 1996;  24 774-782
    PubMedGoogle Scholar
  • 40 Charbonnier B A, Flessinger J N, Banga J D, Wenzel E, D'Azemar P, Sagnard L. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis.  Thromb Haemost . 1998;  79 897-901
    PubMedGoogle Scholar
  • 41 Spiro T E, and the Enoxaparin Clinical Trial Group. Clinical use of low molecular weight heparins.  Thromb Haemost . 1997;  373 (373)
    PubMedGoogle Scholar
  • 42 Hull R D, Raskob G E, Pineo G F. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.  N Engl J Med . 1992;  326 975-982
    CrossrefPubMedGoogle Scholar
  • 43 Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.  Thromb Haemost . 1994;  72 186-190
    PubMedGoogle Scholar
  • 44 Fiessinger J N, Lopez-Fernandez M, Gatterer E. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.  Thromb Haemost . 1996;  76 195-199
    PubMedGoogle Scholar
  • 45 Warkentin T E, Elavathil L J, Hayward C PM, Johnston M A, Russett J I, Kelton J G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.  Ann Intern Med . 1997;  127 804-812
    CrossrefPubMedGoogle Scholar
  • 46 Warkentin T E, Chong B H, Greinacher A. Heparin-induced thrombocytopenia: towards consensus.  Thromb Haemost . 1998;  79 1-7
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Chong B H. Low molecular weight heparinoid and heparin-induced thrombocytopenia.  Aust NZ J Med . 1996;  26 331
    PubMedGoogle Scholar
  • 48 Magnani H N. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172).  Thromb Haemost . 1993;  70 554-561
    PubMedGoogle Scholar
  • 49 De Valk W H, Banga J D, Wester J WJ. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.  Ann Intern Med . 1995;  123 1-9
    PubMedGoogle Scholar
  • 50 Greinacher A, Janssens U, Berg G. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.  Circulation . 1999;  100 587-593
    CrossrefPubMedGoogle Scholar
  • 51 Schiele F, Lindgaerde F, Eriksson H. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial.  Thromb Haemost . 1997;  77 834-838
    PubMedGoogle Scholar
  • 52 Hyers T M, Agnelli G, Hull R D. Antithrombotic therapy for venous thromboembolic disease.  Chest . 1998;  114 561S-578S
    PubMedGoogle Scholar
  • 53 Harrison L, Johnston M, Massicotte M P, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy.  Ann Intern Med . 1997;  126 133-136
    PubMedGoogle Scholar
  • 54 Crowther M A, Ginsberg J S, Kearon C. A randomized trial comparing 5 mg and 10 mg warfarin loading doses.  Arch Intern Med . 1999;  159 46-48
    CrossrefPubMedGoogle Scholar
  • 55 Hirsh J, Lensing A. Thrombolytic therapy for deep vein thrombosis.  Int Angiol . 1996;  5 S22-S25
    PubMedGoogle Scholar
  • 56 Elliot M S, Immelman E J, Jeffery P. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial.  Br J Surg . 1979;  66 838-843
    CrossrefPubMedGoogle Scholar
  • 57 Turpie A GG, Levine M N, Hirsh J. Tissue plasminogen activator (rt-PA) vs Heparin in deep vein thrombosis.  Chest . 1990;  97 172S-175S
    PubMedGoogle Scholar
  • 58 Schweizer J, Kirch W, Koch R. Short- and long-term results after thrombolytic treatment of deep vein thrombosis.  J Am Coll Cardiol . 2000;  36 1336-1343
    PubMedGoogle Scholar
  • 59 Bloemenkamp K W, Rosendaal F R, Helmerhorst F M, Vandenbroucke J P. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects.  Arch Intern Med . 2000;  160 49-52
    CrossrefPubMedGoogle Scholar
  • 60 Mewissen M W, Seabrook G R, Meissner M H, Cynamon J, Labropoulos N, Haughton S H. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry [published erratum appears in Radiology 1999 Dec;213:930].  Radiology . 1999;  211 39-49
    CrossrefPubMedGoogle Scholar
  • 61 Comerota A J, Throm R C, Mathias S D, Haughton S, Mewissen M. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life.  J Vasc Surg . 2000;  32 130-137
    CrossrefPubMedGoogle Scholar
  • 62 Pacouret G, Alison D, Pottier J M, Bertrand P, Charbonnier B. Free-floating thrombus and embolic risk in patients with angiographically confirmed proximal deep venous thrombosis-a prospective study.  Arch Intern Med . 1997;  157 305-308
    PubMedGoogle Scholar
  • 63 Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism.  Lancet . 1992;  340 873-876
    PubMedGoogle Scholar
  • 64 Levine M N, Hirsh J, Gent M. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.  Thromb Haemost . 1995;  74 606-611
    PubMedGoogle Scholar
  • 65 Schulman S, Rhedin A-S, Lindmarker P. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism.  N Engl J Med . 1995;  332 1661-1665
    CrossrefPubMedGoogle Scholar
  • 66 Prandoni P, Lensing A WA, Buller H R. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer.  N Engl J Med . 1992;  327 1128-1133
    CrossrefPubMedGoogle Scholar
  • 67 Pini M, Aiello S, Manotti C. Low molecular weight heparin versus warfarin the prevention of recurrence after deep vein thrombosis.  Thromb Haemost . 1994;  72 191-197
    PubMedGoogle Scholar
  • 68 Kearon C, Gent M, Hirsh J. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.  N Engl J Med . 1999;  340 901-907
    PubMedGoogle Scholar
  • 69 Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders.  Annu Rev Med . 2000;  51 169-185
    CrossrefPubMedGoogle Scholar
  • 70 Lane D A, Mannucci P M, Bauer K A. Inherited thrombophilia: part 1.  Thromb Haemost . 1996;  76 651-662
    PubMedGoogle Scholar
  • 71 Lane D A, Mannucci P M, Bauer K A. Inherited thrombophilia: part 2.  Thromb Haemost . 1996;  76 824-834
    PubMedGoogle Scholar
  • 72 Rosendaal F R. Venous thrombosis: a multicausal disease.  Lancet . 1999;  353 1167-1173
    CrossrefPubMedGoogle Scholar
  • 73 Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy.  Am J Med . 1998;  104 332-338
    CrossrefPubMedGoogle Scholar
  • 74 Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis.  Thromb Haemost . 1999;  81 165-176
    PubMedGoogle Scholar
  • 75 Eichinger S, Stumpflen A, Hirschl M. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism.  Thromb Haemost . 1998;  80 566-569
    PubMedGoogle Scholar
  • 76 Ridker P M, Miletich J P, Stampfer M J, Goldhaber S Z, Lindpaintner K, Hennekens C H. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism.  Circulation . 1995;  92 2800-2802
    CrossrefPubMedGoogle Scholar
  • 77 Simioni P, Prandoni P, Lensing A WA. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden).  N Engl J Med . 1997;  336 399-403
    CrossrefPubMedGoogle Scholar
  • 78 Eichinger S, Pabinger I, Stumpflen A. The risk of recurrent venous thromboembolism in patients with and without Factor V Leiden.  Thromb Haemost . 1997;  77 624-628
    PubMedGoogle Scholar
  • 79 Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A Allele in the coagulation factor V gene and the G20210A Allele in the prothrombin gene.  Thromb Haemost . 1999;  81 684-689
    Article in Thieme ConnectPubMedGoogle Scholar
  • 80 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood . 1996;  88 3698-3703
    CrossrefPubMedGoogle Scholar
  • 81 Eichinger S, Minar E, Hirschl M. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene.  Thromb Haemost . 1999;  81 14-17
    PubMedGoogle Scholar
  • 82 Margaglione M, Brancaccio V, Giuliani N. Increased risk for venous thrombosis in carriers of the prothrombin G-a 20210 gene variant.  Ann Intern Med . 1998;  129 89-93
    PubMedGoogle Scholar
  • 83 De Stafano V, Martinelli I, Mannucci P M. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.  N Engl J Med . 1999;  341 801-806
    CrossrefPubMedGoogle Scholar
  • 84 Van den Belt G M A, Sanson B J, Simioni P. Recurrence of venous thromboembolism in patients with familial thrombophilia.  Arch Intern Med . 1997;  157 2227-2232
    CrossrefPubMedGoogle Scholar
  • 85 Kryle P, Minar E, Hirschl M. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.  N Engl J Med . 2000;  343 457-462
    CrossrefPubMedGoogle Scholar
  • 86 Kraaijenhagen R A, in't Anker S P, Koopman M M. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism.  Thromb Haemost . 2000;  83 5-9
    Article in Thieme ConnectPubMedGoogle Scholar
  • 87 Hutten B A, Prins M, Gent M, Ginsberg J, Tijssen J, Buller H. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.  J Clin Oncol . 2000;  18 3078-3083
    PubMedGoogle Scholar
  • 88 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism.  N Engl J Med . 2000;  342 1953-1958
    CrossrefPubMedGoogle Scholar
  • 89 Schulman S, Granqvist S, Holmstrom M. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism.  N Engl J Med . 1997;  336 393-398
    CrossrefPubMedGoogle Scholar
  • 90 Landefeld C S, Beyth R J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.  Am J Med . 1993;  95 315-328
    CrossrefPubMedGoogle Scholar
  • 91 Palareti G, Leali N, Coccheri S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT).  Lancet . 1996;  348 423-428
    CrossrefPubMedGoogle Scholar
  • 92 White R H, Beyth R J, Zhou H, Romano P S. Major bleeding after hospitalization for deep-venous thrombosis.  Am J Med . 1999;  107 414-424
    CrossrefPubMedGoogle Scholar
  • 93 Beyth R J, Quinn L M, Landefeld S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.  Am J Med . 1998;  105 91-99
    CrossrefPubMedGoogle Scholar
  • 94 Kuijer P MM, Hutten B A, Prins M H, Buller H R. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism.  Arch Intern Med . 1999;  159 457-460
    CrossrefPubMedGoogle Scholar
  • 95 Poller L, Shiach C R, MacCallum P K. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation.  Lancet . 1998;  352 1505-1509
    CrossrefPubMedGoogle Scholar
  • 96 Palareti G, Legnani C, Lee A. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy.  Thromb Haemost . 2000;  84 805-810
    Article in Thieme ConnectPubMedGoogle Scholar
  • 97 Beyth R J, Quinn L, Landefeld C S. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial.  Ann Intern Med . 2000;  133 687-695
    PubMedGoogle Scholar
  • 98 Margaglione M, Colaizzo D, D'Andrea G. Genetic modulation of oral anticoagulation with warfarin.  Thromb Haemost . 2000;  84 775-778
    PubMedGoogle Scholar
  • 99 Aithal G P, Day C P, Kesteven P J, Daly A K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.  Lancet . 1999;  353 717-719
    CrossrefPubMedGoogle Scholar
  • 100 MacCallum P K, Brennan P J, Meade T W. Minimum effective intensity of oral anticoagulant therapy in primary prevention of coronary heart disease.  Arch Intern Med . 2000;  160 2462-2468
    CrossrefPubMedGoogle Scholar
  • 101 Bynum L J, Wilson J E. Low-dose heparin therapy in the long-term management of venous thromboembolism.  Am J Med . 1979;  67 553-556
    CrossrefPubMedGoogle Scholar
  • 102 Hull R, Delmore T, Carter C. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.  N Engl J Med . 1982;  306 189-194
    PubMedGoogle Scholar
  • 103 Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (fragmin) in patients with venous thromboembolism and contraindications to coumarin.  Thromb Haemost . 1994;  71 7-11
    PubMedGoogle Scholar
  • 104 Das S K, Cohen A T, Edmondson R A, Melissari E, Kakkar V V. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial.  World J Surg . 1996;  20 521-527
    CrossrefPubMedGoogle Scholar
  • 105 Lopaciuk S, Bielska-Falda H, Noszczyk W. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.  Thromb Haemost . 1999;  81 26-31
    PubMedGoogle Scholar
  • 106 Gonzalez-Fajardo J A, Arreba E, Castrodeza J. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.  J Vasc Surg . 1999;  30 283-292
    CrossrefPubMedGoogle Scholar
  • 107 Veiga F, Escriba A, Maluenda M P. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.  Thromb Haemost . 2000;  84 559-564
    PubMedGoogle Scholar
  • 108 Hirsh J, Weitz J. New antithrombotic agents.  Lancet . 1999;  353 1431-1436
    CrossrefPubMedGoogle Scholar
  • 109 Brandjes D PM, Büller H R, Heijboer H. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis.  Lancet . 1997;  349 759-762
    CrossrefPubMedGoogle Scholar
  • 110 Grady D, Wenger N K, Herrington D. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study.  Ann Intern Med . 2000;  132 689-696
    PubMedGoogle Scholar
  • 111 White R H, Zhou H, Romano P S. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California.  Ann Intern Med . 1998;  128 737-740
    CrossrefPubMedGoogle Scholar
      >